title: Comment on: Schnitzlers syndrome--exacerbation after anti-TNF treatment.
authors.forename: H D
authors.initials: HD
authors.lastname: de Koning
authors.forename: J W M
authors.initials: JW
authors.lastname: van der Meer
authors.forename: A
authors.initials: A
authors.lastname: Simon
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor; D019873:Schnitzler Syndrome / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D053590:Interleukin 1 Receptor Antagonist Protein; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept